Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24455242 | 0.81 | NOS2 (0.43) | NOS2PDE3BPDE3ANOS3CYP3A4 | |
| SCHEMBL9019314 | 0.75 | NOS2 (0.50) | NOS2GABRA1PDE3BPDE3ANOS3 | |
| SCHEMBL8686292 | 0.73 | GABRA1 (0.40) | NOS2GABRA1GABRB2NOS3CYP3A4 | |
| SCHEMBL9847068 | 0.71 | GABRA1 (0.47) | GABRA1GABRB2CYP3A4TRPA1 | |
| SCHEMBL27069703 | 0.70 | GABRA1 (0.34) | GABRA1GABRB2CYP3A4TRPA1 | |
| SCHEMBL8156690 | 0.70 | GABRA1 (0.59) | GABRA1GABRB2CYP3A4TRPA1 | |
| SCHEMBL19006356 | 0.68 | NOS2 (0.52) | NOS2PDE3BPDE3ANOS3CYP3A4 | |
| SCHEMBL21567686 | 0.68 | NOS2 (0.56) | NOS2PDE3BPDE3ANOS3CYP3A4 | |
| SCHEMBL295649 | 0.68 | CYP3A4 (0.50) | GABRA1GABRB2CYP3A4TRPA1 | |
| SCHEMBL28258615 | 0.67 | GABRA1 (0.41) | NOS2GABRA1GABRB2CYP3A4TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025896-A1 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | AMGEN INC. (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2022109242-A1 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3- YL)PYRIDOF[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | AMGEN INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025896-A1 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | HINT1, DPYD, NME2 | NOS2 3022/4885GABRA1 4437/4885GABRB2 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.